

December 4, 2019

Re: NSABP B-31: *A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC→T) to that of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC→T + H) in Node-Positive Breast Cancer Patients Who Have Tumors that Overexpress HER2*

Dear Patient:


You have taken part in the clinical trial NSABP B-31, which is now coming to an end. We would like to take this opportunity to thank you for the contributions that you have made to cancer research. Because of your participation, we have gained more information to help us answer some important scientific questions.

We will no longer be collecting information about you from your doctors and nurses. However, it is important that you continue to see your doctor for regular checkups. Your doctor may have recommendations for tests such as mammograms, gynecologic exams, blood work, or other exams.

In 2005, the initial results of the NSABP B-31 were published. At that time the NSABP provided you with the results of the study. Since that time additional articles have been published reporting more results of the study. If you wish to read more about the results of the study you participated in, we have included references to publications about this study. These publications can be found at medical libraries. We recommend that you discuss the results of the study with your doctor.

Once again, thank you for your very important contribution to cancer research.

Sincerely,



Norman Wolmark, MD
NRG Oncology, Group Chair

REFERENCES FOR NSABP PROTOCOL B-31 PUBLICATIONS

Romond E, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson N, Tan-Chiu E, Martino S, Paik S, Kaufman D, Swain SM, Pisansky T, Fehrenbacher L, Kutteh LA, Vogel V, Visscher DW, Yothers G, Jenkins RB, Brown A, Dakhil S, Mamounas EP, Lingle WL, Klein P, Ingle JN, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N Engl J Med* 2005;353(16):1673-84.

Romond E, Jeong JH, Rastogi P, Swain SM, Geyer CE Jr, Ewer MS, Rathi V, Fehrenbacher L, Brufsky A, Seay TE, Azar C, Flynn PJ, Zapas JL, Polikoff J, Gross HM, Biggs DD, Atkins JN, Tan-Chiu E, Zheng P, Yothers G, Mamounas EP, Wolmark N. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and

cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. *J Clin Oncol* 2012;30(31):3792-99.

Perez EA, Romond EH, Suman VJ, Jeong J-H, Sledge G, Geyer CE, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas M, Zujewski JA, Wolmark N. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831. *J Clin Oncol* 2014; 32: 3744-52.

Ganz PA, Romond E, Cecchini RS, Rastogi P, Geyer CE, Swain SM, Jeong JH, Fehrenbacher L, Gross HM, Brufsky A, Flynn P, Wahl T, Seay TE, Wade JL, Biggs DD, Atkins J, Polikoff J, Zapas JL, Mamounas EP, Wolmark N. Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31: A randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide followed by paclitaxel to that of doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in node-positive breast cancer patients who have tumors that overexpress HER2. *J Clin Oncol* 2017;35(35):3942-3948.